Neuropathic cancer pain, may result from tumor invasion of nervous tissue, surgical nerve damage during tumor removal, radiation-induced nerve damage, chemotherapy-related neuropathy, or may be of benign origin unrelated to cancer.Cancer pain includes a 30% neuropathic component Pain is prevalent in patients with cancer and considerably undermines their quality of life, thereby making the development of a comprehensive pain management approach essential.Although from a pathophysiological perspective neuropathic cancer pain may differ from chronic neuropathic pain (i.e.noncancer-related), clinical practice and limited publications have shown that these two pain entities may share some treatment modalities.Coanalgesics drugs like antidepressant and anticonvulsant agents, are recommended by evidence-based guidelines, whereas others, such as lidocaine patch 5%, are supported by randomized, controlled, clinical trial data.The remarkable effectiveness of oxycodone for neuropathic pain provides the possibility that muopioid receptor agonists, which have different pharmacological profile with morphine, can be used for the management of neuropathic pain.According to WHO guidelines, neuropathic cancer pain can be relieved using a multimodal treatment approach as the majority of cancer patients suffer from multiple types of pain.Review of available bibliography reveals that the management of neuropathic cancer pain has changed dramatically in the past few years, thanks to (a) the improved perception of the problem, (b) the new therapeutic approaches and (c) novel drugs.In our Pain center in Greece we have accumulated great experience for the management of NCP.